A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer.
BACKGROUND: Despite previous studies, uncertainty has persisted about the role of thymidylate synthase (TS) and p53 status as markers of prognosis in colorectal cancer (CRC). PATIENTS AND METHODS: A total of 967 patients accrued to a large adjuvant trial in CRC were included in a prospectively plan...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2006
|
| _version_ | 1797059113157394432 |
|---|---|
| author | Popat, S Chen, Z Zhao, D Pan, H Hearle, N Chandler, I Shao, Y Aherne, W Houlston, R |
| author_facet | Popat, S Chen, Z Zhao, D Pan, H Hearle, N Chandler, I Shao, Y Aherne, W Houlston, R |
| author_sort | Popat, S |
| collection | OXFORD |
| description | BACKGROUND: Despite previous studies, uncertainty has persisted about the role of thymidylate synthase (TS) and p53 status as markers of prognosis in colorectal cancer (CRC). PATIENTS AND METHODS: A total of 967 patients accrued to a large adjuvant trial in CRC were included in a prospectively planned molecular substudy, and of them, 59% had rectal cancer and about 90% received adjuvant chemotherapy (either systemically or randomly allocated to intraportal 5-fluorouracil infusion or both). TS and p53 status were determined, blinded to any clinical data, by immunohistochemistry using a validated polyclonal antibody or the DO-7 clone, respectively, and their relationships with overall survival were examined. RESULTS: High TS expression was observed in 58% and overexpression of p53 in 60% of tumours. TS expression correlated with tumour stage, and p53 overexpression, with rectal cancers. There was no evidence that either marker was significantly associated with survival by either univariate (TS hazard ratio (HR) = 0.94, 95% CI 0.76-1.18 and P = 0.6 and p53 HR = 0.98, 95% CI 0.78-1.23 and P = 0.9) or multivariate analyses (TS HR = 0.99, 95% CI 0.79-1.25 and P = 0.9 and p53 HR = 0.98, 95% CI 0.78-1.23 and P = 0.8). CONCLUSIONS: Neither TS nor p53 expression has significant prognostic value in the adjuvant setting of CRC. |
| first_indexed | 2024-03-06T19:59:36Z |
| format | Journal article |
| id | oxford-uuid:26cfb89a-5408-462e-866f-23c6b9846a34 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:59:36Z |
| publishDate | 2006 |
| record_format | dspace |
| spelling | oxford-uuid:26cfb89a-5408-462e-866f-23c6b9846a342022-03-26T12:03:19ZA prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:26cfb89a-5408-462e-866f-23c6b9846a34EnglishSymplectic Elements at Oxford2006Popat, SChen, ZZhao, DPan, HHearle, NChandler, IShao, YAherne, WHoulston, R BACKGROUND: Despite previous studies, uncertainty has persisted about the role of thymidylate synthase (TS) and p53 status as markers of prognosis in colorectal cancer (CRC). PATIENTS AND METHODS: A total of 967 patients accrued to a large adjuvant trial in CRC were included in a prospectively planned molecular substudy, and of them, 59% had rectal cancer and about 90% received adjuvant chemotherapy (either systemically or randomly allocated to intraportal 5-fluorouracil infusion or both). TS and p53 status were determined, blinded to any clinical data, by immunohistochemistry using a validated polyclonal antibody or the DO-7 clone, respectively, and their relationships with overall survival were examined. RESULTS: High TS expression was observed in 58% and overexpression of p53 in 60% of tumours. TS expression correlated with tumour stage, and p53 overexpression, with rectal cancers. There was no evidence that either marker was significantly associated with survival by either univariate (TS hazard ratio (HR) = 0.94, 95% CI 0.76-1.18 and P = 0.6 and p53 HR = 0.98, 95% CI 0.78-1.23 and P = 0.9) or multivariate analyses (TS HR = 0.99, 95% CI 0.79-1.25 and P = 0.9 and p53 HR = 0.98, 95% CI 0.78-1.23 and P = 0.8). CONCLUSIONS: Neither TS nor p53 expression has significant prognostic value in the adjuvant setting of CRC. |
| spellingShingle | Popat, S Chen, Z Zhao, D Pan, H Hearle, N Chandler, I Shao, Y Aherne, W Houlston, R A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. |
| title | A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. |
| title_full | A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. |
| title_fullStr | A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. |
| title_full_unstemmed | A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. |
| title_short | A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. |
| title_sort | prospective blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer |
| work_keys_str_mv | AT popats aprospectiveblindedanalysisofthymidylatesynthaseandp53expressionasprognosticmarkersintheadjuvanttreatmentofcolorectalcancer AT chenz aprospectiveblindedanalysisofthymidylatesynthaseandp53expressionasprognosticmarkersintheadjuvanttreatmentofcolorectalcancer AT zhaod aprospectiveblindedanalysisofthymidylatesynthaseandp53expressionasprognosticmarkersintheadjuvanttreatmentofcolorectalcancer AT panh aprospectiveblindedanalysisofthymidylatesynthaseandp53expressionasprognosticmarkersintheadjuvanttreatmentofcolorectalcancer AT hearlen aprospectiveblindedanalysisofthymidylatesynthaseandp53expressionasprognosticmarkersintheadjuvanttreatmentofcolorectalcancer AT chandleri aprospectiveblindedanalysisofthymidylatesynthaseandp53expressionasprognosticmarkersintheadjuvanttreatmentofcolorectalcancer AT shaoy aprospectiveblindedanalysisofthymidylatesynthaseandp53expressionasprognosticmarkersintheadjuvanttreatmentofcolorectalcancer AT ahernew aprospectiveblindedanalysisofthymidylatesynthaseandp53expressionasprognosticmarkersintheadjuvanttreatmentofcolorectalcancer AT houlstonr aprospectiveblindedanalysisofthymidylatesynthaseandp53expressionasprognosticmarkersintheadjuvanttreatmentofcolorectalcancer AT popats prospectiveblindedanalysisofthymidylatesynthaseandp53expressionasprognosticmarkersintheadjuvanttreatmentofcolorectalcancer AT chenz prospectiveblindedanalysisofthymidylatesynthaseandp53expressionasprognosticmarkersintheadjuvanttreatmentofcolorectalcancer AT zhaod prospectiveblindedanalysisofthymidylatesynthaseandp53expressionasprognosticmarkersintheadjuvanttreatmentofcolorectalcancer AT panh prospectiveblindedanalysisofthymidylatesynthaseandp53expressionasprognosticmarkersintheadjuvanttreatmentofcolorectalcancer AT hearlen prospectiveblindedanalysisofthymidylatesynthaseandp53expressionasprognosticmarkersintheadjuvanttreatmentofcolorectalcancer AT chandleri prospectiveblindedanalysisofthymidylatesynthaseandp53expressionasprognosticmarkersintheadjuvanttreatmentofcolorectalcancer AT shaoy prospectiveblindedanalysisofthymidylatesynthaseandp53expressionasprognosticmarkersintheadjuvanttreatmentofcolorectalcancer AT ahernew prospectiveblindedanalysisofthymidylatesynthaseandp53expressionasprognosticmarkersintheadjuvanttreatmentofcolorectalcancer AT houlstonr prospectiveblindedanalysisofthymidylatesynthaseandp53expressionasprognosticmarkersintheadjuvanttreatmentofcolorectalcancer |